Hologic

Optas, LLC Acquires 3,058 Hologic Inc Shares for $227,790

Hologic Receives FDA Approval for Aptima HPV Assay Primary Screening Option

Robert Olstein's Strategic Moves: Exiting Hologic Inc with a -1.44% Impact

Hologic Misses Q4 Revenue Estimates, Sales Rise 2.5% YoY to $1.05B

豪洛捷

Hologic Q1 FY26 revenue up 2.5% to $1,047.8mln.

Catalyst<ul> <li>The company maintains strong cash reserves relative to market value.</li> <li>MACD Death Cross signals on January 23 and January 26 indicate a bullish bias for HOLX.</li></ul>Risk<ul> <li>Market expectations for HOLX tend to be optimistic but show differences among analysts.</li> <li>Overall fund flow trends for HOLX are negative with large and extra-large order sizes showing outflows.</li></ul>

Key Factors

Optas, LLC acquired 3,058 shares of Hologic Inc (HOLX) for $227,790, initiating a new position in the company. Hologic received FDA approval for its Aptima HPV Assay as a primary screening option for cervical cancer detection.

HOLX News